Journal article
Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies
LH Porter, SG Harrison, GP Risbridger, Natalie Lister, RA Taylor
Journal of Steroid Biochemistry and Molecular Biology | Elsevier | Published : 2024
Abstract
Prostate cancer is primarily hormone-dependent, and medical treatments have focused on inhibiting androgen biosynthesis or signaling through various approaches. Despite significant advances with the introduction of androgen receptor signalling inhibitors (ARSIs), patients continue to progress to castration-resistant prostate cancer (CRPC), highlighting the need for targeted therapies that extend beyond hormonal blockade. Chimeric Antigen Receptor (CAR) T cells and other engineered immune cells represent a new generation of adoptive cellular therapies. While these therapies have significantly enhanced outcomes for patients with hematological malignancies, ongoing research is exploring the bro..
View full abstractRelated Projects (1)
Grants
Awarded by Astellas Pharma US
Funding Acknowledgements
Fellowship and grant support was obtained from the National Health and Medical Research Council, Australia (G.P.R., APP1102752; G.P.R., Project Grant APP1138242; R.A.T., L.H.P., Ideas Grant APP2011391; N. L. Ideas Grant APP 2028153; G.P.R., R.A.T., Synergy Grant APP2026555), the Department of Health and Human Services acting through the Victorian Cancer Agency (R.A.T, Fellowship MCRF15023, CAPTIV Program), Cancer Council Victoria (L.H.P., Grant-in-Aid TP834128; N.L., Venture Grant; L.H.P., Postdoctoral Research Fellowship), Tour de Cure (R.A.T., RSP-515-2024), Prostate Cancer Foundation of Australia (L.H.P., PIRAYI-0322), Monash University (N.L., Future Leader Postdoctoral Fellowship FLPF23-1952570271, Faculty of Medicine, Nursing and Health Sciences), the EJ Whitten Foundation, Movember (GAP Xenografting Consortium), the Peter and Lyndy White Foundation, TissuPath Pathology, and the Rotary Club of Manningham.r and Medical Research Council, Australia (G.P.R., APP1102752; G.P.R., Project Grant APP1138242; R.A.T., L.H.P., Ideas Grant APP2011391; N. L. Ideas Grant APP 2028153; G.P.R., R.A.T., Synergy Grant APP2026555) , the Department of Health and Human Services acting through the Victorian Cancer Agency (R.A.T, Fellowship MCRF15023, CAPTIV Program) , Cancer Council Victoria (L.H.P., Grant-in-Aid TP834128; N.L., Venture Grant; L.H.P., Postdoctoral Research Fellow-ship) , Tour de Cure (R.A.T., RSP-515-2024) , Prostate Cancer Founda-tion of Australia (L.H.P., PIRAYI-0322) , Monash University (N.L., Future Leader Postdoctoral Fellowship FLPF23-1952570271, Faculty of Medi-cine, Nursing and Health Sciences) , the EJ Whitten Foundation, Move-mber (GAP Xenografting Consortium) , the Peter and Lyndy White Foundation, TissuPath Pathology, and the Rotary Club of Manningham.